Top Markets
Coin of the day
Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276
Pozycja w akcjach #509
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Cena akcji
$7.88
Kapitalizacja rynkowa
$50.25B
Zmiana (1 dzień)
-1.11%
Zmiana (1 rok)
-7.06%
Kraj
CN
Handel Jiangsu Hengrui Medicine Co., Ltd. (600276)

Kategoria

Historia stopy dywidendy dla Jiangsu Hengrui Medicine Co., Ltd. (600276)
Stopa dywidendy (TTM) dla Jiangsu Hengrui Medicine Co., Ltd. (symbol akcji: 600276) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Jiangsu Hengrui Medicine Co., Ltd. (600276) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji